Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study

Kenneth L. Jones | A. Hattersley | S. Ellard | T. Tuomi | F. Cadario | M. Polak | H. Cavé | P. Njølstad | D. Gašperíková | J. Stanik | T. Klupa | M. Małecki | K. Patel | I. Klimeš | Z. Punthakee | V. Iotova | I. Rabbone | T. Skrivarhaug | S. Flanagan | P. Juliusson | E. Codner | E. Tjora | L. Legault | G. Chiari | T. Kapellen | F. Cameron | R. Holl | K. Raile | N. Shehadeh | E. Hathout | S. Tumini | R. Bonfanti | Marielisa Rincon | J. V. D. van den Bergh | D. Mul | N. Thomas | V. Saxena | D. Iafusco | H. Irgens | F. Barbetti | E. Pearson | Neville J. Howard | José M C L Silva | J. Aisenberg | A. Bertrand | R. Nuboer | M. Shepherd | C. Bizzarri | A. Chakera | E. D. Franco | Jan Walker | S. Hasegawa | J. Ho | S. O’Connell | Janine Sanchez | J. Meulen | R. Coutant | M. Delvecchio | M. Szopa | C. Metz | D. Deiss | D. Carson | R. V. Velde | A. Uehara | E. Faleschini | A. Jaap | J. Beltrand | J. Weill | R. Mcvie | M. Schebek | A. Burrows | H. Woodhead | R. Mathew | P. Bowman | V. Hakeem | S. O'Riordan | M. Hoarau | L. Barák | E. Piccinno | D. Schmidt | V. Cauvin | I. Akkurt | D. Hill | T. Ford | T. Babiker | Roisin Finn | T. Williams | P. Voorhoeve | R. Chetan | G. Modgil | A. Werner | M. Cartigny | A. K. Høgåsen | Ian Hunter | F. Mathews | J. Houghton | Ellen Kaufman | R. Pesavento | H. Abdul-Latif | E. Cummings | U. Menzel | A. Klinge | H. Bruel | M. Paĺko | P. Lambert | E. Heffernan | A-L Fauret | Natalie Hughes | Liz Davis | G. Vermeulen | Uma Visser | R. Krishnaswamy | Åsta Sulen | Pernille Svalastoga | Ellen H Tessmann | Javier Ilker Hussein Anees Lubomir Joop Anne-Marie Carla Aisenberg Akkurt Abdul-Latif Al-Abdullah Ba | A. Al-Abdullah | B. Couch | A. Dankovčíková | Bastian De Gallen | Padma Guntamukkala | R. Hoddinott | Helena Kuulasmaa | Sorin Iocara | Tony Lafferty | O. Malievsky | S. Muther | Janani Kumaraguru Pillai | S. Pruhova | Danette Rose | Susan Sandereson | Julian P.H. Shiels | T. Tinklin | T. Weisner | Rønnaug øddegård | Janani K Pillai | A.M. Burrows | Henrik Irgens | D. Hill | Tarig Babiker | Anthony M. Burrows | P. Júlíusson

[1]  M. Msall,et al.  ADHD, learning difficulties and sleep disturbances associated with KCNJ11‐related neonatal diabetes , 2017, Pediatric diabetes.

[2]  A. Hattersley,et al.  Precision diabetes: learning from monogenic diabetes , 2017, Diabetologia.

[3]  L. Philipson,et al.  Patients with KCNJ11‐related diabetes frequently have neuropsychological impairments compared with sibling controls , 2016, Diabetic medicine : a journal of the British Diabetic Association.

[4]  I. Tannock,et al.  Limits to Personalized Cancer Medicine. , 2016, The New England journal of medicine.

[5]  A. Hattersley,et al.  Psychiatric morbidity in children with KCNJ11 neonatal diabetes , 2016, Diabetic medicine : a journal of the British Diabetic Association.

[6]  R. Scharfmann,et al.  Sulfonylurea Therapy Benefits Neurological and Psychomotor Functions in Patients With Neonatal Diabetes Owing to Potassium Channel Mutations , 2015, Diabetes Care.

[7]  A. Hattersley,et al.  The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study , 2015, The Lancet.

[8]  F. Ashcroft,et al.  Systemic Administration of Glibenclamide Fails to Achieve Therapeutic Levels in the Brain and Cerebrospinal Fluid of Rodents , 2015, PloS one.

[9]  D. Dunger,et al.  ISPAD Clinical Practice Consensus Guidelines 2014. Assessment and management of hypoglycemia in children and adolescents with diabetes. , 2014, Pediatric diabetes.

[10]  R. Scharfmann,et al.  Neuropsychological dysfunction and developmental defects associated with genetic changes in infants with neonatal diabetes mellitus: a prospective cohort study [corrected]. , 2013, The lancet. Diabetes & endocrinology.

[11]  M. Msall,et al.  Visuomotor Performance in KCNJ11-Related Neonatal Diabetes Is Impaired in Children With DEND-Associated Mutations and May Be Improved by Early Treatment With Sulfonylureas , 2012, Diabetes Care.

[12]  F. Cadario,et al.  No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes , 2011, Diabetologia.

[13]  Lucimary C. Gurgel,et al.  Long-term response to sulfonylurea in a patient with diabetes due to mutation in the KCNJ11 gene. , 2010, Arquivos brasileiros de endocrinologia e metabologia.

[14]  F. Ashcroft,et al.  Muscle Dysfunction Caused by a KATP Channel Mutation in Neonatal Diabetes Is Neuronal in Origin , 2010, Science.

[15]  J. Skupień,et al.  Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up. , 2010, Diabetes technology & therapeutics.

[16]  H. Hoey.  Psychosocial factors are associated with metabolic control in adolescents: research from the Hvidoere Study Group on Childhood Diabetes , 2009, Pediatric diabetes.

[17]  C. Goldsmith,et al.  A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events , 2007, Diabetes Care.

[18]  F. Ashcroft,et al.  Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. , 2006, The New England journal of medicine.

[19]  A. Hattersley,et al.  Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype , 2006, Diabetologia.

[20]  B. Glaser,et al.  Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. , 2004, The Journal of clinical endocrinology and metabolism.

[21]  A. Hattersley,et al.  Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. , 2004, Diabetes.

[22]  F. Ashcroft,et al.  Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. , 2004, The New England journal of medicine.

[23]  D. Jacobs,et al.  Insulin resistance during puberty: results from clamp studies in 357 children. , 1999, Diabetes.

[24]  R. Holman,et al.  UKPDS 26: sulphonylurea failure in non‐insulin‐dependent diabetic patients over six years , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[25]  J. Levy,et al.  U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease , 1995, Diabetes.

[26]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[27]  Weight Gain Associated With Intensive Therapy in the Diabetes Control and Complications Trial , 1988, Diabetes Care.

[28]  H. Pan,et al.  WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age , 2006 .

[29]  F. Ashcroft,et al.  Perspectives in Diabetes Activating Mutations in Kir 6 . 2 and Neonatal Diabetes New Clinical Syndromes , New Scientific Insights , and New Therapy , 2005 .

[30]  THE BRITISH National Formulary. , 1957, British medical journal.